CO7160011A2 - Compuestos de azetidina y piperidina útiles como inhibidores de pde10 - Google Patents

Compuestos de azetidina y piperidina útiles como inhibidores de pde10

Info

Publication number
CO7160011A2
CO7160011A2 CO15003862A CO15003862A CO7160011A2 CO 7160011 A2 CO7160011 A2 CO 7160011A2 CO 15003862 A CO15003862 A CO 15003862A CO 15003862 A CO15003862 A CO 15003862A CO 7160011 A2 CO7160011 A2 CO 7160011A2
Authority
CO
Colombia
Prior art keywords
azetidine
piperidine compounds
compounds useful
pde10 inhibitors
compounds
Prior art date
Application number
CO15003862A
Other languages
English (en)
Spanish (es)
Inventor
Jennifer R Allen
Jian J Chen
Michael J Frohn
Matthew R Kaller
Qingyian Liu
Thomas T Nguyen
Alexander J Pickrell
Wenyuan Qian
Robert M Rzasa
Wenge Zhong
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48692687&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO7160011(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CO7160011A2 publication Critical patent/CO7160011A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
CO15003862A 2012-06-14 2015-01-08 Compuestos de azetidina y piperidina útiles como inhibidores de pde10 CO7160011A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261659911P 2012-06-14 2012-06-14

Publications (1)

Publication Number Publication Date
CO7160011A2 true CO7160011A2 (es) 2015-01-15

Family

ID=48692687

Family Applications (1)

Application Number Title Priority Date Filing Date
CO15003862A CO7160011A2 (es) 2012-06-14 2015-01-08 Compuestos de azetidina y piperidina útiles como inhibidores de pde10

Country Status (25)

Country Link
US (3) US8691986B2 (cg-RX-API-DMAC7.html)
EP (1) EP2864317A1 (cg-RX-API-DMAC7.html)
JP (1) JP2015519402A (cg-RX-API-DMAC7.html)
KR (1) KR20150023417A (cg-RX-API-DMAC7.html)
CN (1) CN104619694A (cg-RX-API-DMAC7.html)
AP (1) AP2014008136A0 (cg-RX-API-DMAC7.html)
AR (1) AR091436A1 (cg-RX-API-DMAC7.html)
AU (1) AU2013274153B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014031368A2 (cg-RX-API-DMAC7.html)
CA (1) CA2875802A1 (cg-RX-API-DMAC7.html)
CL (1) CL2014003391A1 (cg-RX-API-DMAC7.html)
CO (1) CO7160011A2 (cg-RX-API-DMAC7.html)
CR (1) CR20150012A (cg-RX-API-DMAC7.html)
EA (1) EA201590014A1 (cg-RX-API-DMAC7.html)
HK (1) HK1203935A1 (cg-RX-API-DMAC7.html)
IL (1) IL235901A0 (cg-RX-API-DMAC7.html)
MA (1) MA37748B1 (cg-RX-API-DMAC7.html)
MX (1) MX2014014924A (cg-RX-API-DMAC7.html)
PE (1) PE20150348A1 (cg-RX-API-DMAC7.html)
PH (1) PH12014502780A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201408168UA (cg-RX-API-DMAC7.html)
TN (1) TN2014000510A1 (cg-RX-API-DMAC7.html)
TW (1) TWI508959B (cg-RX-API-DMAC7.html)
UY (1) UY34858A (cg-RX-API-DMAC7.html)
WO (1) WO2013188724A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103221404B (zh) 2010-05-13 2015-12-16 安姆根有限公司 可用作pde10抑制剂的不饱和氮杂环化合物
AR091436A1 (es) * 2012-06-14 2015-02-04 Amgen Inc Compuestos de azetidina y piperidina utiles como inhibidores de pde10

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
CN103221404B (zh) 2010-05-13 2015-12-16 安姆根有限公司 可用作pde10抑制剂的不饱和氮杂环化合物
CA2800578A1 (en) * 2010-05-13 2011-11-17 Amgen Inc. Nitrogen-heterocyclic compounds as phosphodiesterase 10 inhibitors
EP2569302A1 (en) * 2010-05-13 2013-03-20 Amgen, Inc Heteroaryloxyheterocyclyl compounds as pde10 inhibitors
US8952037B2 (en) * 2010-05-13 2015-02-10 Amgen Inc. Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors
AR091436A1 (es) * 2012-06-14 2015-02-04 Amgen Inc Compuestos de azetidina y piperidina utiles como inhibidores de pde10

Also Published As

Publication number Publication date
AU2013274153A1 (en) 2014-12-18
EA201590014A1 (ru) 2015-04-30
JP2015519402A (ja) 2015-07-09
WO2013188724A1 (en) 2013-12-19
MA37748A1 (fr) 2016-11-30
HK1203935A1 (en) 2015-11-06
US20140148435A1 (en) 2014-05-29
MX2014014924A (es) 2015-03-09
TN2014000510A1 (en) 2016-03-30
TW201412729A (zh) 2014-04-01
US8691986B2 (en) 2014-04-08
US9303028B2 (en) 2016-04-05
PE20150348A1 (es) 2015-03-04
PH12014502780A1 (en) 2015-02-02
UY34858A (es) 2013-11-29
CR20150012A (es) 2015-02-11
US20130338138A1 (en) 2013-12-19
AR091436A1 (es) 2015-02-04
MA37748B1 (fr) 2017-07-31
AP2014008136A0 (en) 2014-12-31
BR112014031368A2 (pt) 2017-06-27
US9493459B2 (en) 2016-11-15
CL2014003391A1 (es) 2015-07-10
AU2013274153B2 (en) 2016-05-19
SG11201408168UA (en) 2015-01-29
IL235901A0 (en) 2015-09-24
KR20150023417A (ko) 2015-03-05
CA2875802A1 (en) 2013-12-19
CN104619694A (zh) 2015-05-13
EP2864317A1 (en) 2015-04-29
TWI508959B (zh) 2015-11-21
US20160176874A1 (en) 2016-06-23

Similar Documents

Publication Publication Date Title
CO6630189A2 (es) Compuestos heterocíclicos de nitrógeno útiles como inhibidores de pde10
NI201700056A (es) 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzhéimer
CO6382157A2 (es) Compuestos pirazina como inhibidores de fosfodiesterasa 10
UY32098A (es) Heteroarilos sustituidos
PE20142335A1 (es) Sintesis de compuestos heterociclicos
IN2014KN02601A (cg-RX-API-DMAC7.html)
NZ629996A (en) 2’- substituted carba-nucleoside analogs for antiviral treatment
ECSP16072941A (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
UY33950A (es) Inhibidores de benzodioxano de la producciòn de leucotrieno
BR112015001759A2 (pt) agentes de modulação de atx
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
CR20140071A (es) Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa
ECSP17010238A (es) Compuestos novedosos de pirimidina sustituidos
CO2017001506A2 (es) Compuestos novedosos de pirimidina sustituidos
MX348024B (es) Compuestos de adamantilo.
ECSP13013075A (es) Método de tratamiento de la fiebre dengue
MX374758B (es) Inhibidores de tirosina cinasa de bruton.
MX370010B (es) Inhibidores de tirosina cinasa de bruton.
PE20150674A1 (es) Azaheterociclos como inhibidores de bir2 y/o bir3
MX374759B (es) Inhibidores de tirosina cinasa de bruton.
PH12014502780A1 (en) Azetidine and piperidine compounds useful as pde10 inhibitors
UY32385A (es) Amidas de pirazinona sustituida
MX2014011473A (es) Procedimientos y composiciones de tratamiento de enfermedades vasculares arterioscleroticas.
MX2014002343A (es) Inhibidores de parp.